343 related articles for article (PubMed ID: 21554565)
1. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
Lobmaier PP; Kunøe N; Gossop M; Waal H
CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release naltrexone for opioid dependence.
Lobmaier P; Kornør H; Kunøe N; Bjørndal A
Cochrane Database Syst Rev; 2008 Apr; (2):CD006140. PubMed ID: 18425938
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone: Not Just for Opioids Anymore.
Sudakin D
J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
[TBL] [Abstract][Full Text] [Related]
5. Vivitrex (Alkermes/Cephalon).
Heading CE
Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
[TBL] [Abstract][Full Text] [Related]
6. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Soyka M; Rösner S
Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
[TBL] [Abstract][Full Text] [Related]
7. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
Johnson BA
Expert Opin Pharmacother; 2006 Jun; 7(8):1065-73. PubMed ID: 16722816
[TBL] [Abstract][Full Text] [Related]
8. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
9. Long-acting depot formulations of naltrexone for heroin dependence: a review.
Krupitsky EM; Blokhina EA
Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
[TBL] [Abstract][Full Text] [Related]
10. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
[TBL] [Abstract][Full Text] [Related]
12. [The use of different forms of naltrexone in the treatment of opioid dependence].
Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
[TBL] [Abstract][Full Text] [Related]
13. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
Kunøe N; Lobmaier P; Ngo H; Hulse G
Br J Clin Pharmacol; 2014 Feb; 77(2):264-71. PubMed ID: 23088328
[TBL] [Abstract][Full Text] [Related]
14. Opioid antagonists for alcohol dependence.
Rösner S; Hackl-Herrwerth A; Leucht S; Vecchi S; Srisurapanont M; Soyka M
Cochrane Database Syst Rev; 2010 Dec; (12):CD001867. PubMed ID: 21154349
[TBL] [Abstract][Full Text] [Related]
15. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
Degenhardt L; Gibson A; Mattick RP; Hall W
Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
[No Abstract] [Full Text] [Related]
16. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
Waal H; Frogopsahl G; Olsen L; Christophersen AS; Mørland J
Eur Addict Res; 2006; 12(3):138-44. PubMed ID: 16778434
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
[TBL] [Abstract][Full Text] [Related]
19. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
20. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
